This Article Full Text Full Text (PDF) All Versions of this Article: 49/6/1271    most recent HYPERTENSIONAHA.106.085738v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mitchell, G. F. Search for Related Content PubMed PubMed Citation Articles by Mitchell, G. F. Related Collections Secondary prevention Chronic ischemic heart disease

(Hypertension. 2007;49:1271.)
© 2007 American Heart Association, Inc.

Original Articles

Long-Term Trandolapril Treatment Is Associated With Reduced Aortic Stiffness

The Prevention of Events With Angiotensin-Converting Enzyme Inhibition Hemodynamic Substudy

Gary F. Mitchell; Mark E. Dunlap; Wayne Warnica; Anique Ducharme; J. Malcolm O. Arnold; Jean-Claude Tardif; Scott D. Solomon; Michael J. Domanski; Kathleen A. Jablonski; Madeline M. Rice; Marc A. Pfeffer for the Prevention of Events With Angiotensin-Converting Enzyme Inhibition Investigators

From the Cardiovascular Engineering, Inc (G.F.M.), Waltham, Mass; Louis Stokes Veterans Affairs Medical Center (M.E.D.), Cleveland, Ohio; Foothills Hospital (W.W.), Calgary, Alberta, Canada; Montreal Heart Institute (A.D., J.-C.T.), Montreal, Quebec, Canada; London Health Sciences Centre (J.M.O.A.), London, Ontario, Canada; Brigham and Women’s Hospital (S.D.S., M.A.P.), Boston, Mass; National Heart, Lung, and Blood Institute (M.J.D.), Bethesda, Md; and Biostatistics Center (K.A.J., M.M.R.), George Washington University, Rockville, Md.

Correspondence to Gary F. Mitchell, Cardiovascular Engineering, Inc, 51 Sawyer Rd, Suite 100, Waltham, MA 02453. E-mail GaryFMitchell{at}mindspring.com

The Prevention of Events with Angiotensin Converting Enzyme inhibition (PEACE) trial evaluated angiotensin-converting enzyme inhibition with trandolapril versus placebo added to conventional therapy in patients with stable coronary disease and preserved left ventricular function. The PEACE hemodynamic substudy evaluated effects of trandolapril on pulsatile hemodynamics. Hemodynamic studies were performed in 300 participants from 5 PEACE centers a median of 52 months (range, 25 to 80 months) after random assignment to trandolapril at a target dose of 4 mg per day or placebo. Central pulsatile hemodynamics and carotid–femoral pulse wave velocity were assessed by using echocardiography, tonometry of the carotid and femoral arteries, and body surface transit distances. Patients randomly assigned to trandolapril tended to be older (mean±SD: 64.2±7.9 versus 62.9±7.7 years; P=0.14), with a higher body mass index (28.5±4.0 versus 27.8±3.9 kg/m²; P=0.09) and lower ejection fraction (57.1±8.1% versus 58.7±8.4%; P<0.01). At the time of the hemodynamic substudy, the trandolapril group had lower mean arterial pressure (93.1±10.2 versus 96.3±11.3 mm Hg; P<0.01) and lower carotid-femoral pulse wave velocity (geometric mean [95% CI]: 10.4 m/s [10.0 to 10.9 m/s] versus 11.2 m/s [10.7 to 11.8 m/s]; P=0.02). The difference in carotid–femoral pulse wave velocity persisted (P<0.01) in an analysis that adjusted for baseline characteristics and follow-up mean pressure. In contrast, there was no difference in aortic compliance, characteristic impedance, augmentation index, or total arterial compliance. Angiotensin-converting enzyme inhibition with trandolapril produced a modest reduction in carotid–femoral pulse wave velocity, a measure of aortic wall stiffness, beyond what would be expected from blood pressure lowering or differences in baseline characteristics alone.

Key Words: angiotensin-converting enzyme • coronary artery disease • randomized clinical trial • arterial stiffness • pulse wave velocity

This article has been cited by other articles:

				A. Upadhyay, S.-J. Hwang, G. F. Mitchell, R. S. Vasan, J. A. Vita, P. I. Stantchev, J. B. Meigs, M. G. Larson, D. Levy, E. J. Benjamin, et al. Arterial Stiffness in Mild-to-Moderate CKD J. Am. Soc. Nephrol., September 1, 2009; 20(9): 2044 - 2053. [Abstract] [Full Text] [PDF]

				M Wong, S P Oakley, L Young, B Y Jiang, A Wierzbicki, G Panayi, P Chowienczyk, and B Kirkham Infliximab improves vascular stiffness in patients with rheumatoid arthritis Ann Rheum Dis, August 1, 2009; 68(8): 1277 - 1284. [Abstract] [Full Text] [PDF]

				M. Madero, C. L. Wassel, C. A. Peralta, S. S. Najjar, K. Sutton-Tyrrell, L. Fried, R. Canada, A. Newman, M. G. Shlipak, M. J. Sarnak, et al. Cystatin C Associates with Arterial Stiffness in Older Adults J. Am. Soc. Nephrol., May 1, 2009; 20(5): 1086 - 1093. [Abstract] [Full Text] [PDF]

				W. Lieb, M. G. Larson, E. J. Benjamin, X. Yin, G. H. Tofler, J. Selhub, P. F. Jacques, T. J. Wang, J. A. Vita, D. Levy, et al. Multimarker Approach to Evaluate Correlates of Vascular Stiffness: The Framingham Heart Study Circulation, January 6, 2009; 119(1): 37 - 43. [Abstract] [Full Text] [PDF]

				M. Delahousse, M. Chaignon, L. Mesnard, P. Boutouyrie, M. E. Safar, T. Lebret, M. Pastural-Thaunat, L. Tricot, A. Kolko-Labadens, A. Karras, et al. Aortic Stiffness of Kidney Transplant Recipients Correlates with Donor Age J. Am. Soc. Nephrol., April 1, 2008; 19(4): 798 - 805. [Abstract] [Full Text] [PDF]